Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
124135
Gastric cancer drug market to double to nearly $1.5 billion in 2018
168068
AGROPROMPROEKT doubles design and exploration work in 2007
68782
Use of drug-eluting stents varies widely;
66069
Targacept publicly offering 2.2 million shares
112494
Drugs selling faster in hospitals than chemist shops
152738
Tamoxifen against breast cancer can save lives and reduce medical costs
19593
Drug plans not sustainable
122643
Some tumours come back
94470
Thousands of cancer patients to benefit from new drug
104112
Cancer care heads in a new direction
26795
Benefits of some cancer drugs exaggerated because trials were stopped early
169180
Drug stocks retrench with broader market;
78929
Drug stocks zigzag;
165699
Pharmaceutical markets in India
98057
Gastrointestinal endoscopes market to reach $2.7 billion in 2017
54743
US Oncology unveils new brand campaign
1365
New drug strategy master plan being crafted --